CN103079581B - 用于改进跨上皮电阻的益生菌株 - Google Patents
用于改进跨上皮电阻的益生菌株 Download PDFInfo
- Publication number
- CN103079581B CN103079581B CN201180026423.5A CN201180026423A CN103079581B CN 103079581 B CN103079581 B CN 103079581B CN 201180026423 A CN201180026423 A CN 201180026423A CN 103079581 B CN103079581 B CN 103079581B
- Authority
- CN
- China
- Prior art keywords
- compositions
- bacterial strain
- cncm
- strain
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000006872 improvement Effects 0.000 title abstract description 6
- 239000006041 probiotic Substances 0.000 title description 4
- 230000000529 probiotic effect Effects 0.000 title description 4
- 235000018291 probiotics Nutrition 0.000 title description 4
- 241000186660 Lactobacillus Species 0.000 claims abstract description 16
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 8
- 208000028774 intestinal disease Diseases 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 52
- 230000001580 bacterial effect Effects 0.000 claims description 50
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 28
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 230000003870 intestinal permeability Effects 0.000 claims description 4
- 210000001842 enterocyte Anatomy 0.000 claims description 3
- 235000021001 fermented dairy product Nutrition 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 abstract description 3
- 208000037902 enteropathy Diseases 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- -1 semisolid Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及乳酸菌的用途，其用于改进跨上皮电阻，更特别地用于治疗和/或预防便秘和/或易激性肠病。
Description
技术领域
本发明涉及包含用于改进跨上皮电阻的乳酸菌菌株的组合物。所述组合物尤其适于治疗和/或预防便秘和/或易激性肠病(irritable bowel disease)。
背景技术
肠易激综合征(irritable bowel syndrome,IBS)或痉挛性结肠(spastic colon)是功能性肠病症，其特征为在没有任何可检测的器质性病因的情况下的慢性腹部疼痛、不适、胀气以及肠排便习惯改变。主要症状可以是腹泻或便秘，或二者交替(分别归类为IBS-D、IBS-C)。IBS可始于感染后(post-infectious，IBS-PI)、始于胁迫性生活事件之后，或在无任何其他医学指征的情况下的成年发病。在IBS中，常规的临床检测不会出现异常，但肠对某些刺激(例如气球吹入试验)更为敏感。
IBS是一种非常常见的病症，在任一时间，其影响大约15%的人群。患该病症的女性大约为男性的两倍。IBS是慢性疼痛、疲乏以及其他症状的起因，并且其增加患者的医疗费用，并导致旷工。研究者已报道IBS的高流行率连同增加的费用导致该疾病具有高社会成本。还认为IBS是一种慢性疾病，其可显著影响患者的生活质量。
尽管目前尚法治愈IBS，但有试图缓解症状的治疗方法，包括调整饮食、药物治疗以及心理干预。
已报道益生菌、尤其是乳酸菌菌株有益于治疗和/或预防IBS。这样的菌株的实例公开在WO 2007/036230、WO 03/010297以及WO 2009/080800中。
当肠粘膜屏障发生破坏时，水和血浆蛋白渗入肠腔，肠道细菌则迁移至体循环中。这些因素通常导致发生局部炎症，或更甚者发生全身性败血症。已知细菌脂多糖(LPS)在体内导致粘膜渗透性过高。发现LPS通过氧化机制促进肠屏障机能障碍，并导致渗透性增加；可通过检测见于单层细胞顶面和基面之间的电位差异(称为跨上皮电阻(TEER))而进行评价渗透性的增加。越来越多的证据表明某些益生性共生菌在体外(Resta-Lenert和Barrett，2006;Miyauchi等，2008)和体内缓解肠屏障损害(降低渗透性)，并且有助于减轻IBS和IBD症状。曾对乳酸杆菌和双歧杆菌的所述特性进行过分析(通过TEER评价)。该研究表明通过TEER所检测的屏障电阻增加具有菌株依赖性。还需要有利于屏障完整性和/或降低渗透性(通常通过TEER评价来证实)的其他菌株。需要改进所述特性的菌株。
发明内容
本发明通过提供一种组合物解决了至少一种上述需要，所述组合物包含选自乳酸杆菌和双歧杆菌组成的组的至少一种菌株，所述组合物用于增加肠上皮细胞的跨上皮电阻(TEER)，其中所述菌株选自DN_1160_044(CNCMI-4316，2010年5月19日保藏)和DN_154_0062(CNCM I-4319，2010年5月19日保藏)组成的组。
本发明还涉及一种组合物，所述组合物包含选自DN_116_0044(CNCMI-4316，2010年5月19日保藏)和DN_154_0062(CNCM I-4319，2010年5月19日保藏)组成的组的至少一种菌株，所述组合物用于：
-治疗和/或预防肠病症，优选治疗和/或预防肠渗透性病症(intestinalpermeability disorder)，或
-治疗和/或预防选自IBS、IBD和肠感染组成的组的病症，或
-治疗和/或预防见于老年人、婴儿或肥胖者的病症。
本发明还涉及一种组合物，所述组合物包含选自菌株DN_116_0044(CNCM I-4316，2010年5月19日保藏)和DN_154_0062(CNCM I-4319，2010年5月19日保藏)组成的组的至少一种菌株，所述组合物用于施用于患有选自IBD和IBS组成的组的病症的受试者。
本发明还涉及乳酸菌菌株，所述乳酸菌菌株选自DN_116_0044(CNCMI-4316，2010年5月19日保藏)和DN_154_0062(CNCM I-4319，2010年5月19日保藏)组成的组。本发明还涉及包含所述菌株的组合物。
一方面，本发明还涉及用于降低肠渗透性的上述组合物。
具体实施方式
定义
在本申请中，化合物或组合物的用途不仅旨在涵盖用途自身，任选相关的意图，而且还涵盖具有商业或法律后果的与化合物或组合物相关的任何信息，例如广告，组合物包装上的说明书或建议书，诸如传单的商业载体上的说明书或建议书，宣传材料，广告招贴，出于安全目的、疗效目的或消费者保护目的提交(例如，向诸如欧洲EFSA的管理机构提交)以用于监管注册的文件。
在本申请中，术语“或”具有非排他性。
菌株
本发明的菌株为选自DN_116_0044(CNCM I-4316，2010年5月19日保藏)和DN_154_0062(CNCM I-4319，2010年5月19日保藏)的乳酸杆菌或双歧杆菌。
本文中所提及的所有菌株均根据布达佩斯条约保藏于国际保藏单位法国国家微生物保藏中心(CNCM，Collection Nationale de Cultures deMicroorganisms,25Rue du Docteur Roux,Paris)。
本发明还包括上述菌株，以及衍生自任一亲本菌株的突变菌株或基因转化菌株、优选仍对TEER具有活性的菌株的用途。这些突变菌株或基因转化菌株可以是亲本菌株中的一种或多种内源基因被突变的菌株，其中，所述突变例如用以修饰其某些代谢特性(例如其发酵糖的能力、其对于酸的抗性、其经胃肠道运输的存活性、其后酸化或其代谢物产生)。它们还可为下述菌株，即，通过一种或多种目的基因对亲本菌株进行基因转化而产生的菌株，其中所述基因转化例如用以赋予所述菌株其他生理特性，或使其表达人们期望通过所述菌株而施用的具有治疗或免疫作用的蛋白。
组合物
在本发明的组合物中，所述菌株可以以活菌或非活菌的完整细菌形式使用。可选地，它们可以以细菌裂解物或以细菌级分(bacterial fractions)的形式使用；可通过例如检测其对TEER的特性而选择适于该应用的细菌级分。优选地，所述细菌细胞作为有活力的活细胞存在。
本发明的组合物可为适于施用、特别是口服施用的任何形式。这包括例如固体、半固体、液体以及粉末。由于较易于施用，例如作为饮料，通常优选液体组合物。
所述组合物每克干重可包含例如至少105cfu、优选至少106cfu的上述至少一种菌株，优选上述所有菌株。这些菌株优选选自乳酸杆菌和双歧杆菌组成的组。
当细菌为活菌形式时，所述组合物通常可在每克干重组合物中包含105至1013菌落形成单位(cfu)，优选至少106cfu，更优选至少107cfu，还更优选至少108cfu，最优选至少109cfu。在液体组合物的情况下，这通常对应于每ml为104至1012菌落形成单位(cfu)/ml，优选至少105cfu/ml，更优选至少106cfu/ml，还更优选至少107cfu/ml，最优选至少109cfu/ml。
本发明的组合物的实例为营养组合物，包括食品，特别是乳制品。
所述组合物可为例如乳制品，优选发酵乳制品。以发酵乳制品形式的施用具有低乳糖水平的额外优点，这对于IBS具有进一步的益处。任选地，可存在其他乳酸菌菌株。所述发酵制品可以以液体存在，或以通过干燥发酵液体而获得的干粉形式存在。优选地，所述发酵制品为新鲜制品。未经受严格热处理步骤的新鲜制品的优点是所存在的菌株为活体形式。优选地，所述发酵制品为乳制品，更优选地，为发酵乳和/或发酵乳清。优选地，所述营养组合物为固定、搅拌或可饮用形式的酸乳或发酵乳。优选地，所述发酵制品为乳酪。优选地，所述发酵制品为发酵的植物，例如固定、搅拌或可饮用形式的发酵大豆、谷物和/或水果。
优选地，本发明的营养组合物为婴儿食品，婴儿配方乳或较大婴儿配方乳。优选地，本发明的组合物为营养食品或药品、营养补充剂或医用食品。
本发明的营养组合物还包括食物补充剂以及功能性食物。“食物补充剂”是指由通常用于食品的化合物制成的产品，但为片剂、粉末、胶囊、饮剂或通常与食物无关的任何其他形式，且对人们的健康具有益处。“功能性食物”是对人们的健康也有益处的食物。特别地，食物补充剂和功能性食物可对疾病(例如慢性疾病)具有保护性或治愈性的生理作用。
实施例1：某些菌株的TEER评价
使用PBS洗涤培养上清。之后，将细菌(100cfu/细胞)添加至T84细胞单层的顶面。实验中检测了96个菌株，包括64株双歧杆菌和32株乳酸杆菌。在温育2小时之后，将40ng/ml LPS(L4516,-EPEC-0127:B8)添加至顶面，或不添加LPS。然后，在温育2小时和4小时之后，测量TEER值以估计上皮屏障功能。所有实验独立进行3次，且在存在和不存在LPS的情况下各一式三份。将t=0的T84数值设为100%。在不存在LPS的情况下，T4时的TEER为98.7%，T6时的TEER为100.2%。在存在LPS的情况下，与t=0相比T4时的对照T84为56.2%，T6时的对照T84为46.7%。
根据TEER检测，结果显示在存在和不存在损害性LPS的情况下显著增加上皮完整性的菌株非常少。鼠李糖乳酸杆菌DN 116004(L.rhamnosusDN_116_0044；CNCM I-4316，2010年5月19日保藏)和两歧双歧杆菌DN_154_0062(B.Bifidum DN_154_0062；CNCM I-4319，2010年5月19日保藏)被鉴定为表现出了改进的TEER特性。诸如NCC2705和BB536的基准未显示显著的改进。
表1：显示最佳结果的所选细菌的TEER结果(损害条件下)
***p值<0.01;**p值<0.05;*p值<0.1
表2：显示最佳结果的所选细菌的TEER结果(非损害条件下)
***p值<0.05
Claims (10)
1.组合物在制备用于增加受试者肠上皮细胞的跨上皮电阻(TEER)的药物中的用途，其中所述组合物包含选自乳酸杆菌和双歧杆菌中的至少一种菌株，其中所述菌株选自DN_116_0044(CNCM I-4316)和DN_154_0062(CNCMI-4319)中的菌株，其中每种菌株均增加肠上皮细胞的TEER。
2.组合物在制备用于治疗和/或预防受试者选自肠病症、选自IBS、IBD和肠感染中的病症和见于老年人、婴儿或肥胖者的病症的药物中的用途，其中所述组合物包含选自菌株DN_116_0044(CNCM I-4316)和DN_154_0062(CNCM I-4319)中的至少一种菌株。
3.组合物在制备用于治疗和/或预防受试者选自IBD和IBS的病症的药物中的用途，其中所述组合物包含选自菌株DN_116_0044(CNCM I-4316)和DN_154_0062(CNCM I-4319)中的至少一种菌株。
4.组合物在制备用于治疗和/或预防肠渗透性病症的药物中的用途，其中所述组合物包含选自菌株DN_116_0044(CNCM I-4316)和DN_154_0062(CNCM I-4319)中的至少一种菌株。
5.乳酸菌菌株，所述乳酸菌菌株选自DN_116_0044(CNCM I-4316)和DN_154_0062(CNCM I-4319)中的菌株。
6.组合物，其包含至少一种权利要求5所述的菌株。
7.根据权利要求2至4任一项所述的用途或权利要求6所述的组合物，其中所述组合物是乳制品。
8.根据权利要求7所述的用途或组合物，其中所述组合物是发酵乳制品。
9.根据权利要求1至4、6或7任一项所述的用途或组合物，其中所述组合物每克干重包含至少105cfu的选自乳酸杆菌和双歧杆菌中的至少一种菌株。
10.根据权利要求9所述的用途或组合物，其中所述组合物每克干重包含至少106cfu的选自乳酸杆菌和双歧杆菌中的至少一种菌株。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2010/001536 WO2011148220A1 (en) | 2010-05-28 | 2010-05-28 | Probiotic strains for use in improving transepithelial resistance |
| IBPCT/IB2010/001536 | 2010-05-28 | ||
| PCT/IB2011/052368 WO2011148358A1 (en) | 2010-05-28 | 2011-05-30 | Probiotic strains for use in improving transepithelial resistance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103079581A CN103079581A (zh) | 2013-05-01 |
| CN103079581B true CN103079581B (zh) | 2015-08-05 |
Family
ID=43334416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180026423.5A Active CN103079581B (zh) | 2010-05-28 | 2011-05-30 | 用于改进跨上皮电阻的益生菌株 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9402872B2 (zh) |
| EP (1) | EP2575834B1 (zh) |
| JP (1) | JP5816273B2 (zh) |
| KR (1) | KR101790683B1 (zh) |
| CN (1) | CN103079581B (zh) |
| BR (1) | BR112012030363A2 (zh) |
| CA (1) | CA2800770C (zh) |
| EA (1) | EA024443B1 (zh) |
| ES (1) | ES2514326T3 (zh) |
| MX (1) | MX346332B (zh) |
| PL (1) | PL2575834T3 (zh) |
| PT (1) | PT2575834E (zh) |
| WO (2) | WO2011148220A1 (zh) |
| ZA (1) | ZA201208978B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011148219A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving the enteric nervous system |
| RU2606770C2 (ru) * | 2011-12-21 | 2017-01-10 | Компани Жервэ Данон | Штамм lactobacillus mucosae для получения ферментированных пищевых продуктов |
| WO2014096901A1 (en) | 2012-12-18 | 2014-06-26 | Compagnie Gervais Danone | Strain of bifidobacterium animalis ssp. animalis |
| JP2018521172A (ja) * | 2015-07-10 | 2018-08-02 | ディーエスエム アイピー アセッツ ビー．ブイ． | 炎症性疾患の予防および治療用の食料および／または飼料組成物 |
| WO2023118510A1 (en) | 2021-12-22 | 2023-06-29 | N.V. Nutricia | Mix of specific bifidobacterium species and specific non-digestible oligosaccharides |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1119154C (zh) * | 1998-01-20 | 2003-08-27 | 上海信谊药业有限公司 | 双歧三联活菌制剂及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092163A1 (en) | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| US20060093592A1 (en) * | 2004-10-04 | 2006-05-04 | Nutracea | Synbiotics |
| EP1883695B1 (en) * | 2005-05-16 | 2009-05-27 | Université de Liège | Probiotic bifidobacterial species |
| ES2561629T3 (es) | 2005-09-28 | 2016-02-29 | Nordisk Rebalance A/S | Tratamiento del SII usando como efectores de tratamiento tanto bacterias probióticas como cereales fermentados |
| ES2693584T3 (es) * | 2006-01-27 | 2018-12-12 | Dupont Nutrition Biosciences Aps | Uso de microorganismos probióticos para el tratamiento y prevención de obesidad y trastornos relacionados |
| PL2072053T3 (pl) | 2007-12-21 | 2013-02-28 | Gervais Danone Sa | Sposób zmniejszania obwodu brzucha przez podawanie bakterii bifidobacterium |
| WO2009158384A1 (en) * | 2008-06-27 | 2009-12-30 | The Procter & Gamble Company | Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders |
-
2010
- 2010-05-28 WO PCT/IB2010/001536 patent/WO2011148220A1/en active Application Filing
-
2011
- 2011-05-30 EA EA201291440A patent/EA024443B1/ru not_active IP Right Cessation
- 2011-05-30 BR BR112012030363A patent/BR112012030363A2/pt not_active Application Discontinuation
- 2011-05-30 KR KR1020127034390A patent/KR101790683B1/ko active IP Right Grant
- 2011-05-30 WO PCT/IB2011/052368 patent/WO2011148358A1/en active Application Filing
- 2011-05-30 MX MX2012013835A patent/MX346332B/es active IP Right Grant
- 2011-05-30 ES ES11727794.7T patent/ES2514326T3/es active Active
- 2011-05-30 PT PT117277947T patent/PT2575834E/pt unknown
- 2011-05-30 JP JP2013511784A patent/JP5816273B2/ja active Active
- 2011-05-30 CN CN201180026423.5A patent/CN103079581B/zh active Active
- 2011-05-30 PL PL11727794T patent/PL2575834T3/pl unknown
- 2011-05-30 EP EP11727794.7A patent/EP2575834B1/en active Active
- 2011-05-30 CA CA2800770A patent/CA2800770C/en active Active
- 2011-05-30 US US13/700,482 patent/US9402872B2/en active Active
-
2012
- 2012-11-28 ZA ZA2012/08978A patent/ZA201208978B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1119154C (zh) * | 1998-01-20 | 2003-08-27 | 上海信谊药业有限公司 | 双歧三联活菌制剂及制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EA024443B1 (ru) | 2016-09-30 |
| EA201291440A1 (ru) | 2013-04-30 |
| US20130216510A1 (en) | 2013-08-22 |
| CN103079581A (zh) | 2013-05-01 |
| KR20130141350A (ko) | 2013-12-26 |
| WO2011148220A1 (en) | 2011-12-01 |
| WO2011148358A1 (en) | 2011-12-01 |
| EP2575834A1 (en) | 2013-04-10 |
| BR112012030363A2 (pt) | 2016-08-09 |
| MX2012013835A (es) | 2013-04-08 |
| JP2013527194A (ja) | 2013-06-27 |
| ZA201208978B (en) | 2014-04-30 |
| ES2514326T3 (es) | 2014-10-28 |
| PT2575834E (pt) | 2014-10-01 |
| CA2800770A1 (en) | 2011-12-01 |
| JP5816273B2 (ja) | 2015-11-18 |
| MX346332B (es) | 2017-03-15 |
| PL2575834T3 (pl) | 2015-03-31 |
| CA2800770C (en) | 2019-09-10 |
| EP2575834B1 (en) | 2014-06-25 |
| US9402872B2 (en) | 2016-08-02 |
| KR101790683B1 (ko) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9198940B2 (en) | Probiotic strains for use in improving the enteric nervous system | |
| US20200061132A1 (en) | Strain having ability to inhibit obesity and pharmaceutical composition containing same | |
| US9962415B2 (en) | Lachnospiraceae in the gut microbiota and association with body weight | |
| CA2893822C (en) | Strain of bifidobacterium animalis ssp. animalis | |
| CN103079581B (zh) | 用于改进跨上皮电阻的益生菌株 | |
| Lipinski | Probiotics-are they all created equal? | |
| Lee et al. | HUMAN INTESTINAL MICROBIOTA AND HEALTHY AGING | |
| Dutta et al. | Probiotics and Prebiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |